Journal of Pathology and Translational Medicine

Original Articles

Prevalence of HER2-ultralow breast cancer in South Korea: a multicenter study by reassessment of HER2-zero cases: Min Chong Kim, Eun Yoon Cho, Hee Jin Lee, Ji Shin Lee, Jee Yeon Kim, Wan Seop Kim, Chungyeul Kim, Sun-Young Jun, Hye Jeong Choi, So Mang Lee, Ahrong Kim, Ji-Young Kim, Jeong Yun Shim, Gyungyub Gong, Young Kyung Bae; Received September 17, 2025 Accepted October 21, 2025 Published online February 23, 2026; DOI: https://doi.org/10.4132/jptm.2025.10.22 [Epub ahead of print]

42 View
2 Download

Abstract PDF Supplementary Material: Background
This study aimed to determine the prevalence of human epidermal growth factor receptor 2 (HER2)–ultralow breast cancer among cases initially classified as HER2 immunohistochemistry (IHC) 0 and assess interobserver variability in interpreting low-level HER2 expression. Methods: In this multicenter retrospective study, all invasive breast cancer cases diagnosed between January and December 2022 across 10 Korean institutions were retrieved. Institutional pathologists reexamined HER2 IHC slides originally reported as IHC 0 according to the 2018 American Society of Clinical Oncology/College of American Pathologists guidelines and reclassified them as HER2-null (0), HER2-ultralow (0+), or HER2-low (1+). Slides from 10% of HER2-null and HER2-ultralow cases were digitized for central review and independently assessed by two pathologists, with discrepancies resolved by consensus. Results: Among 8,026 cases, 2,836 cases (35.5%) were initially reported as IHC 0. Upon re-review, 1,673 (59.0%), 1,139 (40.2%), and 24 (0.8%) cases were reclassified as HER2-null, HER2-ultralow, and HER2-low, respectively. The prevalence of HER2-ultralow breast cancer varied considerably across institutions (23.7%–78.1%). Central review of 268 digitized cases showed concordance in 193 cases (72.0%). Among the 75 discordant cases, 54 tumors (72.0%) were upgraded from HER2-null to HER2-ultralow, and 18 (24.0%) tumors were upgraded from HER2-ultralow to HER2-low. Furthermore, two tumors (2.7%) were downgraded from HER2-ultralow to HER2-null. Conclusions: Approximately 40% of cases initially categorized as IHC 0 were reclassified as HER2-ultralow. The substantial inter-institutional variability observed in interpreting low-level HER2 expression highlights the need for standardized training and quality assurance to ensure accurate identification of patients eligible for HER2-targeted antibody–drug conjugates.

CD9 Expression in Colorectal Carcinomas and Its Prognostic Significance: Kyung-Ju Kim, Hee Jung Kwon, Min Chong Kim, Young Kyung Bae; J Pathol Transl Med. 2016;50(6):459-468. Published online October 25, 2016; DOI: https://doi.org/10.4132/jptm.2016.10.02

10,679 View
156 Download
19 Web of Science
16 Crossref

Background
CD9, a member of the tetraspanin superfamily, is a tumor suppressor in many malignancies. The aim of this study was to evaluate the immunohistochemical expression of CD9 in colorectal carcinomas (CRCs) and determine clinicopathological and prognostic significance of its expression.
Methods
The CD9 expression status of 305 CRCs was evaluated using a semi-quantitative scoring system in tumor cells (T-CD9) and immune cells (I-CD9) by classifying the results as high and low expression.
Results
High T-CD9 (T-CD9 [+]) expression was detected in 175 samples (57.6%) and high I-CD9 (I-CD9 [+]) expression was detected in 265 samples (86.9%). Using Kaplan- Meier survival analysis, the T-CD9 (+) group showed a tendency for better disease-free survival (DFS) (p = .057). In left-sided tumors, DFS was significantly longer in the T-CD9 (+) group (p = .021) but no statistical significance was observed with right-sided tumors (p = .453). I-CD9 (+) CRCs significantly correlated with well/moderately differentiation (p = .014). In Kaplan-Meier analysis, the I-CD9 (+) group had a tendency towards worse DFS compared to the I-CD9 (–) group (p = .156). In combined survival analysis of T-CD9 and I-CD9, we found that the longest DFS was among patients in the T-CD9 (+)/I-CD9 (–) group, whereas the T-CD9 (–)/I-CD9 (+) group showed the shortest DFS (p = .054).
Conclusions
High expression of T-CD9 was associated with a favorable DFS, especially in left-sided CRCs. Combined evaluation of T-CD9 and I-CD9 is required to determine the comprehensive prognostic effect of CD9 in CRCs.

Citations

Citations to this article as recorded by

Predicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines
Alexandra Razumovskaya, Mariia Silkina, Andrey Poloznikov, Timur Kulagin, Maria Raigorodskaya, Nina Gorban, Anna Kudryavtseva, Maria Fedorova, Boris Alekseev, Alexander Tonevitsky, Sergey Nikulin
Frontiers in Molecular Biosciences.2025;[Epub] CrossRef
Intestinal estrogen receptor beta modulates the murine colon tumor immune microenvironment
Madeleine Birgersson, Matilda Holm, Carlos J. Gallardo-Dodd, Baizhen Chen, Lina Stepanauskaitė, Linnea Hases, Claudia Kutter, Amena Archer, Cecilia Williams
Cancer Letters.2025; 622: 217661. CrossRef
Establishment of Coala: a novel 3D and 2D cancer cell line derived from colorectal cancer liver metastasis
Sandra Mersakova, Juraj Marcinek, Dusan Brany, Olga Chodelkova, Martin Vorcak, Martin Cermak, Martina Poturnajova, Zuzana Kozovska, Henrieta Skovierova, Slavomira Novakova, Barbora Mitruskova, Dusan Loderer, Marian Grendar, Veronika Holubekova, Andrea Hor
Human Cell.2025;[Epub] CrossRef
CD9, a tetraspanin in cancer: biology and therapeutic promise in acute leukemia
Océane Guého, Elie Cousin, Jérémie Rouger-Gaudichon, Anne-Gaëlle Rio, Sébastien Corre, Virginie Gandemer, Frédéric Mazurier
Oncogenesis.2025;[Epub] CrossRef
Proteomic analysis of plasma exosomes in patients with metastatic colorectal cancer
Zhaoyue Zhong, Jiayin Ji, Hongxia Li, Ling Kang, Haipeng Zhu
Clinical Proteomics.2024;[Epub] CrossRef
Prognostic value and multifaceted roles of tetraspanin CD9 in cancer
Róbert Ondruššek, Barbora Kvokačková, Karolína Kryštofová, Světlana Brychtová, Karel Souček, Jan Bouchal
Frontiers in Oncology.2023;[Epub] CrossRef
Proteomic Signature of Extracellular Vesicles Associated with Colorectal Cancer
Natalia Soloveva, Svetlana Novikova, Tatiana Farafonova, Olga Tikhonova, Victor Zgoda
Molecules.2023; 28(10): 4227. CrossRef
Anti-Human CD9 Fab Fragment Antibody Blocks the Extracellular Vesicle-Mediated Increase in Malignancy of Colon Cancer Cells
Mark F. Santos, Germana Rappa, Simona Fontana, Jana Karbanová, Feryal Aalam, Derek Tai, Zhiyin Li, Marzia Pucci, Riccardo Alessandro, Chikao Morimoto, Denis Corbeil, Aurelio Lorico
Cells.2022; 11(16): 2474. CrossRef
The Study of the Extracellular Matrix in Chronic Inflammation: A Way to Prevent Cancer Initiation?
Asia Marangio, Andrea Biccari, Edoardo D’Angelo, Francesca Sensi, Gaya Spolverato, Salvatore Pucciarelli, Marco Agostini
Cancers.2022; 14(23): 5903. CrossRef
In vivo expansion of a CD9+ decidual-like NK cell subset following autologous hematopoietic stem cell transplantation
Ane Orrantia, Enrique Vázquez-De Luis, Gabirel Astarloa-Pando, Iñigo Terrén, Ainhoa Amarilla-Irusta, Diego Polanco-Alonso, Carmen González, Alasne Uranga, Tomás Carrascosa, Juan J. Mateos-Mazón, Juan C. García-Ruiz, Sergio Callejas, Ana Quintas, Ana Dopaz
iScience.2022; 25(10): 105235. CrossRef
Inhibition of cancer-cell migration by tetraspanin CD9-binding peptide
Thanawat Suwatthanarak, Masayoshi Tanaka, Yoshitaka Miyamoto, Kenji Miyado, Mina Okochi
Chemical Communications.2021; 57(40): 4906. CrossRef
High expression of tumor susceptibility gene 101 (TSG101) is associated with more aggressive behavior in colorectal carcinoma
Elmira Gheytanchi, Leili Saeednejad Zanjani, Roya Ghods, Maryam Abolhasani, Marzieh Shahin, Somayeh Vafaei, Marzieh Naseri, Fahimeh Fattahi, Zahra Madjd
Journal of Cancer Research and Clinical Oncology.2021; 147(6): 1631. CrossRef
Increased CD9 expression predicts favorable prognosis in human cancers: a systematic review and meta-analysis
Hyun Min Koh, Bo Gun Jang, Dong Hui Lee, Chang Lim Hyun
Cancer Cell International.2021;[Epub] CrossRef
Prognostic Value of CD9 in Solid Tumor: A Systematic Review and Meta-Analysis
Ping Zeng, Meng Si, Rui-xia Sun, Xu Cheng, Xiao-yang Li, Min-bin Chen
Frontiers in Oncology.2021;[Epub] CrossRef
Matrix Effect in the Isolation of Breast Cancer-Derived Nanovesicles by Immunomagnetic Separation and Electrochemical Immunosensing—A Comparative Study
Silio Lima Moura, Mercè Martì, María Isabel Pividori
Sensors.2020; 20(4): 965. CrossRef
CD9 expression indicates a poor outcome in acute lymphoblastic leukemia
Peiqi Liang, Miao Miao, Zhuogang Liu, Hongtao Wang, Wei Jiang, Shiyu Ma, Chuan Li, Rong Hu
Cancer Biomarkers.2018; 21(4): 781. CrossRef

First
Prev
Page of 1
Next
Last

Search